Operating income before deduction of amortization: Longeveron (LGVN)

Graphic logo of longeveron.com (LGVN)

The regenerative medicine sector currently relies on the test results of Lomecel-B against Alzheimer's disease. Longeveron Inc. (LGVN) is expanding its capacities in Florida, minimizing reliance on third-party laboratories during drug development. Actual EBITDA demonstrates the business's liquidity vector, where the 0.00 level indicates the state of the parameter. This chart smooths out market noise, helping investors determine the real cash flow.

LGVN (Longeveron) Profit before payment of interest, taxes and amortization history from 11/23/2025 to 11/12/2026

Longeveron (LGVN) - metric breakdowns and financial figures

- stock price and consensus target price:
Price Chart Longeveron Corporation|LGVN - Price Target Chart
- company stock exchange capitalization indicators:
Market Capitalization Longeveron|LGVN - Total Company Value
- balance sheet equity data:
Net Assets per Single Share Longeveron|LGVN - Company Book Value|Market-to-Book Ratio longeveron.com|LGVN - Aggregate Company Assets
- debt level and financial liquidity data:
Debt to Equity Ratio Longeveron Inc.|LGVN - Long-Term Debt to Capital|Short-Term Indebtedness to Equity Longeveron Inc|LGVN - Company Aggregate Debts|Debts to Book Value Longeveron|LGVN - Company Long-Term Liabilities|Company Short-Term Debt Longeveron|Immediate Liquidity longeveron.com
- net income and valuation multiples indicators:
LGVN - Company Net Income|Expected Net Income Longeveron Inc.|LGVN - Price to Earnings Ratio|Projected Price to Earnings Ratio longeveron.com|LGVN - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation Longeveron|LGVN - Operating profit before deduction of amortization|Earnings per share for the trailing year Longeveron|LGVN - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months longeveron.com|LGVN - Earnings per share growth in current year|Projected earnings per share growth rate for next year Longeveron Inc.
Summary company analytics:Longeveron Inc.
Flagship merchandise of Longeveron

Stable utilization of the Longeveron Inc. (LGVN) biomanufacturing complex, coupled with the uninterrupted operation of sterile zones, directly determines cash flow dynamics. Analyzing EBITDA allows for the daily tracking of real business expansion, eliminating quarterly reporting lags. While growth in this indicator confirms the issuer's fundamental strength, purchasing the asset at a local peak on the chart risks a prolonged price drawdown.

Competitor analysis for Longeveron Inc.

Mesoblast Pharma - Profit before payment of interest, taxes and amortization|LCTX - Profit before payment of interest, taxes and amortization|Operating income before deduction of amortization surrozen.com SRZN|cryo-cell.com (CCEL) - Profit before payment of interest, taxes and amortization|FBLG (FibroBiologics) - Profit before payment of interest, taxes and amortization|Profit before payment of interest, taxes and amortization BioRestorative Therapies Inc|Profit before interest, taxes and amortization Creative Medical Technology Holdings Inc. CELZ